Immunotherapy and Cancer Therapeutics: Why Partner?

Cancer Immunotherapy

Volumn , Issue , 2007, Pages 207-233

  Emens, Leisha A ^a   Jaffee, Elizabeth M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955300341     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012372551-6/50076-6     Document Type: Chapter

References (175)

1. Almand B., Resser J., Lindman B., Nadaf S., Clark J., Kwon E., Carbone D., Gabrilovich D. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6:1755-1766.
2. Anderson M., Venanzi E., Klein L., Chen Z., Berzins S., Turley S., von Boehmer H., Bronson R., Dierich A., Benoist C., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-1401.
3. Anichini A., Mortarini R., Nonaka D., Molla A., Vegetti C., Montaldi E., Wang X., Ferrone S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer Stage III and IV melanoma patients. Cancer Res. 2006, 66:6405-6411.
4. Antonia S., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., Bepler G., Simon G., Janssen W., Lee J., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 2006, 12:878-887.
5. Arlen P., Gulley J.P.C., Skarupa L., Pazdur M., Panicali D., Beetham P., Tsang K., Grosenbach D., Feldman J., Steinberg S., et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12:1260-1269.
6. Arnould L., Gelly M., Penault-Liorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., et al. Trastuzumabbased treatment of HER-2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?. Brit. J. Cancer 2006, 94:259-267.
7. Attia P., Phan G., Maker A., Robinson M., Yang J., Sherry R., Topalian S., Kammula U., Royal R., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23:6043-6053.
8. Baldwin T., Hogquist K., Jameson S. The fourth way? Harnessing aggressive tendencies in the thymus. J. Immunol. 2004, 173:6515-6520.
9. Bansal-Pakala P., Jember A.-H., Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 2001, 7:907-912.
10. Beck K., Blansfield J., Tran K., Feldman A., Hughes M., Royal R., Kammula U., Topalian S., Sherry R., Kleiner D., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006, 24:2283-2289.
11. + T-cell response. Nat. Rev. Immunol. 2004, 4:595-602.
12. hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
13. Bocci G., Nicolaou K., Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic agents. Cancer Res. 2002, 62:6938-6943.
14. Borrello I., Sotomayor E., Rattis F.-M., Cooke S., Gu L., Levitsky H. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000, 95:3011-3019.
15. Braun D., Crist K., Shaheen F., Staren E., Andrews S., Parker J. Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity. Amer. J. Surg. 2005, 190:570-571.
16. Byrd-Leifer C.A., Block E.F., Takeda K., Akira S., Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur. J. Immunol 2001, 31:2448-2457.
17. Casares N., Pequignot N., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exper. Med. 2006, 202:1691-1701.
18. Castilleja A., Ward N., O'Brian C., Swearingen B.N., Swan E., Gillogly M., Murray J., Kudelka A., Gershenson D., Ioannides C. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol. Cell. Biochem. 2001, 217:21-33.
19. Chapoval A., Ni J., Lau J., Wilcox R., Flies D., Liu D., Dong H., Sica G., Zhu G., Tamada K., et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2001, 2:269-274.
20. Cho B., Rao V., Ge Q., Eisen H., Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exper. Med. 2000, 192:549-556.
21. Chopra A., Kim T., O-Sullivan I., Martinez D., Cohen E. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based vaccine. Inter J. Cancer 2006, 118:2888-2898.
22. Chu Y., Wang L., Yang G., Ross H., Urba W., Prell R., Jooss K., Xiong S., Hu H. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinomas. J. Immunother. 2006, 29:367-380.
23. Clynes R., Towers T., Presta L., Ravetch J. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6:443-446.
24. + T cell responses and anti-tumor immunity. Cancer Res. 2006, 66:4904-4912.
25. Coral S., Sigalotti L., Altomonte M., Engelsberg A., Colizzi F., Cattarossi I., Maraskowsky E., Lager E., Seliger B., Maio M. 5-aza-2'-Deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: Immunotherapeutic implications. Clin. Cancer Res. 2002, 8:2690-2695.
26. *02/01 restricted, CEA-peptide-specific cytotoxic T cells in vivo. Inter. J. Cancer. 2003, 104:437-445.
27. Correale P., Cusi M., Tsang K., Del Vecchio M., Marsili S., Placa M., Intrivici G., Aquino A., Micheli L., Nencini C., et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony stimualting factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J. Clin. Oncol. 2005, 23:8950-8958.
28. Curiel T., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K., Daniel B., Zimmermann M., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
29. Dannull J., Su Z., Rizzieri D., Yang B., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115:3623-3633.
30. Davis T., Czerwinski D., Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies car result in the loss of CD20 antigen expression. Clin. Cancer Res. 1999, 5:611-615.
31. Demaria S., Volm M., Shapiro R., Yee H., Oratz R., Formenti S., Muggia F., Symmans W. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin. Cancer Res. 2001, 7:3025-3030.
32. Deng Z., Zhu W., Lu C., Shi Q., Ju S., Ma H., Xu Y., Zhang X. An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits the proliferation of a myeloma line. Hybrid Hybridomics 2004, 23:176-182.
33. Diehl L., den Boer A., Schoenberger S., van der Voort E., Schumacher T., Melief C., Offringa R., Toes R. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 1999, 5:774-779.
34. Donepudi M., Raychaudhuri P., Bluestone J., Mokyr M. Mechanism of Melphalan-induced B7-1 gene expression in P815 tumor cells. J. Immunol. 2001, 166:6491-6499.
35. Dong H., Strome S., Salomao D., Tamura H., Hirano E., Flies D., Roche P., Lu J., Zhu G., Tamada K., et al. Timor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
36. Drake C., Doody A., Mihalyo M., Huang C., Kelleher E., Ravi S., Hipkiss E., Flies D., Kennedy E., Long M., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7:239-249.
37. Dudley M., Wunderlich J., Robbins P., Yang J., Hwu P., Schwartwentruber D., Topalian S., Sherry R., Restifo N., Hibicki A., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
38. Dudley M., Wunderlich J., Yang J., Sherry R., Topalian S., Restifo N., Royal R., Kammula U., White D., Mavroukakis S., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastastic melanoma. J. Clin. Oncol. 2005, 23:2346-2357.
39. Egen J., Kuhns M., Allison J. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3:611-618.
40. Emens L., Armstrong D., Biedrzycki B., Davidson N., Davis-Sproul J., Fetting J., Jaffee E., Onners B., Piantadosi S., Reilly R., et al. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Human Gene Ther. 2004, 15:313-337.
41. Emens L.A. Trastuzumab: Targeted therapy for the management of HER-2/neu-overex pressing metastatic breast cancer. Amer. J. Ther. 2005, 12:243-253.
42. Emens L.A., Machiels J.P., Reilly R.T., Jaffee E.M. Chemotherapy: Friend or foe to cancer vaccines?. Curr. Opin. Mol. Ther. 2001, 3:77-84.
43. Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004, 6:R275-R283.
44. + T cells to the antitumor immune response. J. Exper. Med. 2005, 201:1591-1602.
45. + T cell immunity to reject established tumors. Blood 2006, 107:1342-1351.
46. Freeman G., Long A., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L., Malenkovich N., Okazaki T., Byrne M., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exper. Med. 2000, 192:1027-1034.
47. Gabrilovich D., Ishida T., Nadaf S., Ohm J., Carbone D. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 1999, 5:2963-2970.
48. Gallegos A., Bevan M. Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J. Exper. Med. 2004, 200:1039-1049.
49. Gennari R., Menard S., Fagnoni F., Ponchio L., Seelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER-2. Clin. Cancer Res. 2004, 10:5650-5655.
50. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Europ. J. Immunol. 2004, 34:336-344.
51. Giles F., Cortes J., Kantarjian H. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. Curr. Mol. Med. 2005, 5:615-623.
52. Gillard G., Farr A. Contrasting models of promiscuous gene expression by thymic epithelium. J. Exper. Med. 2005, 202:15-19.
53. Goldrath A., Bogatzki L., Bevan M. Naive T cells transiently aquire a memory-like phenotype during homeostasis-driven proliferation. J. Exper. Med. 2000, 192:557-564.
54. Gonzalez L., Loyet K., Calemine-Fenaux J., Chauhan V., Wranik B., Ouyang W., Eaton D. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attentuator and herpesvirus entry mediator. Proc. Natl. Acad. Sci. USA 2005, 102:1116-1121.
55. Greenwald R., Freeman G., Sharpe A. The B7 family revisited. Am. Rev. Immunol. 2005, 23:515-548.
56. Grohmann U., Orabona C., Fallarino F., Vacca C., Calcinaro F., Falorni A., Candeloro P., Belladonna M., Bianchi R., Fioretti M., et al. CTLA-4 Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 2002, 3:1097-1101.
57. Hammerling G., Schonrich G., Momburg F., Auphan N., Malissen M., Malissen B., Schmitt-Verhulst A., Arnold B. Non-deletional mechanisms of peripheral and central tolerance: Studies with transgenic mice with tissue-specific expression of a foreign MHC class I antigen. Immunol. Rev. 1991, 122:47-67.
58. Heath W., Carbone F. Cross-presentation, dendritic cells, tolerance, and autoimmunity. Ann. Rev. Immunol. 2001, 19:47-64.
59. Hodi F., Mihm M., Soiffer R., Haluska F., Butler M., Seiden M., Davis T., Henry-Spires R., MacRae S., Willman A., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 2003, 100:4712-4717.
60. Hogquist K., Baldwin T., Jameson S. Central tolerance: Learning self-control in the thymus. Nat. Rev. Immunol. 2005, 5:772-782.
61. Hong H., Lee J., Park S., Kang Y., Chang S., Kim K., Kim J., Murthy K., Payne J., Yoon S., et al. A humanized 4-1BB monoclonal antibody suppresses antigen-induced humoral immune responses in non-human primates. J. Immunother. 2000, 23:613-621.
62. Hu H., Poehlein C., Urba W., Fox B. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002, 62:3914-3919.
63. Hurwitz A., Yu T., Leach D., Allison J. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 1998, 18:10067-10071.
64. Inoue S., Leitner W., Golding B., Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 2006, 66:7741-7747.
65. Inoue S., Slaton J., Perrotte P., Davis D., Bruns C., Hicklin D., McConkey D., Sweeney P., Radinsky R., Dinney C. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. 2000, 6:4874-4884.
66. Ito F., Li Q., Shreiner A., Okuyama R., Jure-Kunkel M., Teitz-Tennenbaum S., Chang A. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004, 64:8411-8419.
67. Jaffee E., Hruban R., Biedrzycki B., Laheru D., Schepers K., Sauter P., Goemann M., Coleman J., Grochow L., Donehower R., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J. Clin. Oncol. 2001, 19:145-156.
68. Jasinska J., Wagner S., Radauer C., Sedivy R., Brodowicz T., Wiltschke C., Breiteneder H., Pehamberger H., Scheiner O., Wiedermann U., et al. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of HER-2/neu. Inter. J. Cancer 2003, 107:976-983.
69. Jenkins M., Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exper. Med. 1987, 165:302-319.
70. Kageshita R., Hirai S., Ono T., Hicklin D., Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression. Amer. J. Pathol. 1999, 154:745-754.
71. Kawasaki K., Akashi S., Shimazu R., Yoshida S., Miyake K., Nishijima M. Mouse Toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J. Biol. Chem. 2000, 275:2251-2254.
72. Khoury s., Sayegh M. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004, 20:529-538.
73. Klapper L., Waterman H., Sela M., Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000, 60:3384-3388.
74. Knutson K., Dang Y., Lu H., Lukas J., Amand B., Gad E., Azeke E., Disis M. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J. Immunol. 2006, 177:84-91.
75. Knutson K.L., Almand B., Dang Y., Disis M.L. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004, 64:1146-1151.
76. + regulatory T cells. J. Exper. Med. 2005, 202:885-891.
77. Kocak E., Lute K., Chang X., May K.J., Exten K., Zhang H., Abdessalam S., Lehman A., Jarjoura D., Zheng P., et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 2006, 66:7276-7284.
78. Kono K., Sato E., Naganuma H., Takahashi A., Mimura K., Nukui H., Fujii H. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin. Cancer Res. 2004, 10:2538-2544.
79. Krambeck A., Thompson R., Dong H., Lohse C., Park E., Kuntz S., Leibovich B., Blute M., Cheville J., Kwon E. B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc. Natl. Acad. Sci. USA 2006, 103:10391-10396.
80. Kryczek I., Wei S., Zou L., Zhu G., Mottram P., Xu H., Chen L., Zou W. Cutting edge: Induction of B7-H4 on APCs through IL-10: Novel suppressive mode for regulatory T cells. J. Immunol. 2006, 177:40-44.
81. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exper. Med. 2006, 203:871-881.
82. Kyewski B., Derbinski J. Self-representation in the thymus: An extended view. Nat. Rev. Immunol. 2004, 4:688-698.
83. Laheru D., Nemunaitis J., Biedrzychi B. A feasibility study of a GM-CSF-secreting irradiated whole cell allogeneic vaccine (GVAX) alone or in sequence wtih Cytoxan for patients with locally advanced or metastatic pancreatic cancer. Presented at the Proceedings of the AACR: Pancreatic Cancer 2005-Advances and Challenges 2005.
84. Latchman Y., Wood C., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A., Brown J., Nunes R., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
85. Liu G., Black K., Yu J. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev. Vacc. 2006, 5:233-247.
86. Loeffler M., Kruger J., Reisfeld R. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res. 2005, 65:5027-5030.
87. + cytolytic T cells. J. Immunol. 2004, 173:5445-5450.
88. +T regulatory cell function implicated in enhanced immune response by low dose cyclophosphamide. Blood 2005, 105:2862-2868.
89. Luznik L., Slansky J., Jalla S., Borrello I., Levitsky H., Pardoll D., Fuchs E. Successful therapy of metastatic cancer using tumor vacciens in mixed allogeneic bone marrow chimeras. Blood 2003, 101:1645-1652.
90. Machiels J., Reilly R., Emens L., Ercolini A., Lei R., Weintraub D., Okoye F., Jaffee E. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 2001, 61:3689-3697.
91. Mackall C., Bare C., Granger L., Sharrow S., Titus J., Gress R. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 1996, 156:4609-4616.
92. Maker A., Phan G., Attia P., Yang J., Sherry R., Topalian S., Kammula U., Royal R., Haworth L., Levy C., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen-4 blockade and interleukin 2: A phase I/II study. Annals Surg. Oncol. 2005, 12:1005-1016.
93. Marincola F., Jaffee E., Hicklin D., Ferrone S. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance. Adv. Immunol. 2000, 74:181-273.
94. Masopust D., Kaech K., Wherry E., Ahmed R. The role of programming in memory T-cell development. Curr. Opin. Immunol. 2004, 16:217-225.
95. Maxwell J., Weinberg A., Prell R., Vella A. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 2000, 164:107-112.
96. + T cells. Cancer Res. 2002, 62:3459-3465.
97. McAdam A., Greenwald R., Levin M., Chernova t., Malenkovich N., Ling V., Freeman G., Sharpe A. ICOS is critical for CD40-mediated antibody class-switching. Nature 2001, 409:102-105.
98. McGargill M., Derbinski J., Hogquist K. Receptor editing in developing T cells. Nat. Immunol. 2000, 1:336-341.
99. Meissner M., Reichert T., Kunkel M., Gooding W., Whiteside T., Ferrone S., Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cellcarcinoma: Association with clinical outcome. Clin. Cancer Res. 2005, 11:2552-2560.
100. Melero I., Shuford W., Newby S., Aruffo A., Ledbetter J., Hellstrom K., Mittler R., Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997, 3:682-685.
101. Mellor A., Munn D. Tryptophan catabolism and regulation of adaptive immunity. J. Immunol. 2003, 170:5809-5813.
102. Mercader M., Bodner B., Moser M., Kwon P., Park E., Manecke R., Ellis T., Wojcik E., Yang D., Flanigan R., et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. USA 2001, 98:14565-14570.
103. Mohsin S., Wiess H., Gutierrez M., Chamness G., Schiff R., Digiovanna M., Wang C., Hilsenbeck S., Osborne C., Allred D., et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol. 2005, 23:2460-2468.
104. Montgomery R., Makary E., Schiffman K., Goodell V., Disis M. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005, 65:650-656.
105. + T cell tolerance to an endogenous tumor antigen. J. Immunol. 2006, 176:974-983.
106. Nalbandian G., Kovats S. Understanding sex biases in immunity: Effects of estrogen on the differentation and function of antigen presenting cells. Immunol. Res. 2005, 31:91-106.
107. Nalbandian G., Pahrkova-Vatchkova V., Mao A., Nale S., Kovats S. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J. Immunol. 2005, 175:2666-2675.
108. Neelapu S., Kwak L., Kobrin C., Reynolds C., Janik J., Dunleavy K., White T., Harvey L., Pennington R., Stetler-Stevenson M., et al. Vaccine-induced tumor-specific immunity despite severe B cell depletion in mantle cell lymphoma. Nat. Med. 2005, 11:986-991.
109. Nigam A., Yacavone R., Zahurak M., Johns C., Pardoll D., Piantadosi S., Levitsky H., Nelson W. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF secreting cancer cell vaccines. Inter. J. Cancer 1998, 12:161-170.
110. Nowak A., Lake R., Marzo A., Scott B., Heath W., Collins E., Frelinger J., Robinson B. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8T cells. J. Immunol. 2003, 170:4905-4913.
111. Nowak A., Robinson B., Lake R. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003, 63:4490-4496.
112. Nowak A., Robinson B., Lake R. Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy. Cancer Res. 2002, 62:2353-2358.
113. Ochsenbein A., Klenerman P., Karrer U., Ludewig B., Pericin M., Hengartner H., Zinkernagel R. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. USA 1999, 96:2233-2238.
114. Ogino T., Bandoh N., Hayashi T., Miyokawa N., Harabuchi Y., Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin. Cancer Res. 2003, 8:4043-4051.
115. Ohm J., Gabrilovich D., Sempowski G., Kisseleva E., Parman K., Nadaf S., Carbone D. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003, 101:4878-4886.
116. Olszewski A., Grossbanrd M. Empowering targeted therapy: Lessons from rituximab. Science STKF 2004, 241:pe30.
117. Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat. Rev. Immunol. 2003, 3:383-391.
118. Pardoll D. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2002, 2:227-238.
119. Pentcheva-Hoang T., Egen J., Wojnoonski K., Allison J. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004, 21:401-413.
120. Perez-Diaz A., Spiess P., Restifo N., Matzinger P., Maricola F. Intensity of the vaccineeelicited immune response determines tumor clearance. J. Immunol. 2002, 168:338-347.
121. Pircher H., Rohrer U., Moskophidis D., Zinkernagel R., Hengartner H. Lower receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature 1991, 351:482-485.
122. Prasad D., Nguyen T., Li Z., Yang D., Duong J., Wang Y., Dong C. Murine B7-H3 is a negative regulator of T cells. J. Immunol. 2004, 173:2500-2506.
123. Prell R., Gearin L., Simmons A., Vanroey M., Jooss K. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol. Immunother. 2006, 12:1-9.
124. Quezada S., Peggs K., Curran M., Allison J. CTLA-4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 2006, 116:1935-1945.
125. Radhakrishnan S., Celis E., Pease L. B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc. Natl. Acad. Sci. USA 2005, 102:11438-11443.
126. Radhakrishnan S., Nguyen L., Ciric B., Flies D., Van Keulen V., Tamada K., Chen L., Rodriguez M., Pease L. Immunotherpeutic potential of B7-DC (PD-12) cross-linking antibody in conferring antitumor immunity. Cancer Res 2004, 64:4965-4972.
127. Radhakrishnan S., Nguyen L., Ciric B., Ure D., Zhou B., Tamada K., Dong H., Tseng S., Shin T., Pardoll D., et al. Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J. Immunol. 2003, 170:1830-1838.
128. Redmond W., Sherman L. Peripheral tolerance of CD8 lymphocytes. Immunity 2005, 22:275-284.
129. Reilly R., Machiels J., Emens L., Ercolini A., Okyoe F., Lei R., Weintraub D., Jaffee E. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expessing tumors. Cancer Res. 2001, 61:880-883.
130. Ribas A., Camacho L., Lopez-Berestein G., Pavlov D., Bulanhagul C., Millham R., Comin-Antluix B., Reuben J., Seja E., Parker C., et al. Antitumor activity in melanoma and anti-self responses in a phase 1 trial with anti-cytotoxic T lymphocyte-associated antigen-4 monoclonal antibody CP-675,206. J. Clin. Oncol. 2005, 23:8968-8977.
131. Salceda S., Tang T., Kmet M., Munteanu A., Ghosh M., Macina R., Liu W., Pilkington G., Papkoff J. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exper. Cell Res. 2005, 306:128-141.
132. Sanderson K., Scotland R., Lee P., Liu D., Groshen S., Snively J., Sian S., Nichol G., Davis T., Keler T., et al. Autoimmunity in a phase 1 trial of a fully human anti-cytotoxic T-lymphocyte-antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 2005, 23:741-750.
133. high T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer. Blood 2000, 95:2024-2030.
134. Schiller J., Nemunaitis J., Ross H. A phase 2 randomized study of GM-CSF genemodified autologous tumor vaccine (CG8123) with and without low dose cyclophosphamide in advanced stage non-small cell lung cancer (NSCLC). Presented at the International Association for the Study of Lung Cancer 2005 2005.
135. Sedy J., Gavrieli M., Potter K., Hurchla M., Lindsley R., Hildner K., Scheu S., Pfeffer K., Ware C., Murphy T., et al. B and T lymphocyte allentuator regulates T cell activation through interaction with herpesvirus entry mediato. Nat. Immunol. 2005, 6:90-98.
136. + cytotoxic T cells. Leukemia 2001, 15:1619-1626.
137. + T cells independent of the PD-1 receptor. J. Exper. Med. 2003, 198:31-38.
138. Shin T., Yoshimura K., Shin T., Crafton E., Tsuchiya H., Housseau E., Koseki H., Schulick R., Chen L., Pardoll D. in vivo co-stimulatory role of B7-DC in tuning T helper cell and cytotoxic T lymphocyte responses. J. Exper. Med. 2005, 201:1531-1541.
139. Sica G., Choi I., Zhu G., Tamada K., Wang S., Tamura H., Chapoval A., Flies D., Bajorath J., Chen L. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 2003, 18:849-861.
140. Sojka D., Donepudi M., Bluestone J., Mokyr M. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J. Immunol. 2000, 164:6230-6236.
141. + T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 1999, 5:780-787.
142. Strome S., Dong H., Tamura H., Voss S., Flies D., Tamada K., Salomao D., Cheville J., Hirano F., Lin W., et al. B7-H1 blockade augments adoptive T cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003, 63:6501-6505.
143. Sugamura K., Ishii N., Weinberg A. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat. Rev. Immunol. 2004, 4:420-431.
144. Suh W., Gajewska B., Okada H., Gronski M., Bertram E., Dawicki W., Duncan G., Bukczynski J., Plyte S., Elia A., et al. The B7 family member B7-H3 preferentially down-regulates T helper type I-mediated immune responses. Nat. Immunol. 2003, 4:899-906.
145. + reglatory T cells in antitumor therapy reveals alternative pathways for suppression of utoreactive cytotoxic T lymphocyte responses. J. Exper. Med. 2001, 194:823-832.
146. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clincal Cancer Res 2005, 11:6713-6721.
147. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Menard C., Ghiringhelli F., Terne M., Carpentier A., Darrasse-Jeze G., et al. Chemoimmuno-therapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J. Immunol. 2006, 176:2722-2729.
148. Takeda I., Ine S., Killeen N., Ndhlovu L., Murata K., Satomi S., Sugamura K., Ishii N. Distinct roles for the OX40-XO40 ligand interaciton in regulatory and nonregulatory T cells. J. Immunol. 2004, 172:3580-3589.
149. Teshima T., Liu C., Lowler K., Dranoff G., Ferrara J. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res 2002, 62:796-800.
150. Teshima T., Mach N., Hill G., Pan L., Gillessen S., Dranoff G., Ferrara J Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 2001, 61:162-171.
151. + T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exper. Med. 2004, 200.
152. Tong A., Stone M. Prospects for CD-40-directed experimental therapy of human cancer. Cancer Gene Ther. 2002, 10:1-13.
153. Tong Y., Song W., Crystal R. Combined intratumoral injection of bone-marrow-derived dendriatic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001, 61:7530-7535.
154. Tringler B., Zhuo S., Pilkington G., Torkko K., Singh M., Lucta M., Heinz D., Papkoff J., Shroyer K. B7-H4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 2005, 11:1842-1848.
155. Tseng S., Otsuji M., Gorski K., Huang X., Slansky J., Pai S., Shalabi A., Shin T., Pardoll D., Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 2001, 193:839-846.
156. van Elsas A., Hurwitz A., Allison J. Combination immunotherapy of B16 melanoma using anti-cytotoic T lymphocyte-macrophage colonystimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigeentation. J. Exp. Med. 1999, 190:355-366.
157. Van Keulen V., Ciric B., Radharkrishnan S., Heckman K., Mitsunaga Y., Ijima K., Kita H., Rodriguez M., Pease L. Immunomodulation using the recombinant monoclonal human B7-DC crosslinking antibody rHlgM12. Clin Exp Immunol 2006, 143:314-321.
158. Vega M., Herta-Yepaz S., Garban H., Jazirehi C., Emmanouilides C., Bonavida B Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance. Oncogene 2004, 23:3530-3540.
159. Vereecque R., Saudemont A., Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004, 18:1223-1230.
160. von Mehren M., Arlen P., Gulley J., Rogatko A., Cooper H., Meropol A., Alpaugh R., Davey M., McLaughlin S., Beard M., et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 2001, 7:1181-1191.
161. Walker L., Abbas A. The enemy within: Keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2001, 21:11-19.
162. + T cell responses by ICOS/B7h costimulation. J. Immunol. 2001, 167:123-139.
163. Wang F., Huang C., Kanagawa O. Rapid deletion of rearranged T cell antigen receptor (TCR) Va-Ja segment by secondary rearrangement in the thymus: Role of continuous rearrangement of TCRa chain gene and positive selection in the T cell repertoire formation. Proc. Natl. Acad. Sci. USA 1998, 95:11834-11839.
164. Wang J., Kobayashi M., Han M., Choi S., Takano M., Hishino S., Tanaka J., Kondoh T., Kawamura K., Hosokawa M. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Brit. J. Hematol. 2002, 11:638-645.
165. Watts T. TNF-TNFR family members in costimulation of T cell responses. Ann. Rev. Immunol. 2005, 23:23-68.
166. Weihrauch M., Ansen S., Jurkiewicz E., Geisen C., Xia Z., Anderson K., Gracien E., Schmidt M., Wittig B., Diehl V., et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 2005, 15:5993-6001.
167. + T cells. J. Exp. Med. 2001, 194:953-966.
168. Wilcox R., Flies D., Zhu G., Johnson A., Tamada K., Chapoval A., Strome S., Pease L., Chen L. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 2002, 109:651-659.
169. + T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J. Immunol. 2003, 171:2161-2169.
170. Yang F., Haluska F. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme-and Fas-mediated pathways. J. Immunol. 2004, 172:4599-4608.
171. Yu B., Kusmartsev S., Cheng F., Paolini M., Nefedova Y., Sotomayor E., Gabrilovich D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced stage experimental breast cancer. Clin. Cancer Res. 2003, 9:285-294.
172. Yu P., Lee Y., Liu W., Chin R., Wang J., Wang Y., Schietinger A., Phillip A., Schreiber H., Fu Y. Priming of native T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 2004, 5:141-149.
173. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat. Rev. Cancer. 2005, 5:263-274.
174. Zou W. Regulatory T cells, tumor immunity, and immunotherapy. Nat. Rev. Immunol. 2006, 6:295-307.
175. Zum Buschenfelde C., Hermann C., Schmidt B., Peschel C., Bernhard H. Anti-human epidermal growth factor receptor-2 (HER-2) monoclonal antibody Trastuzumab enhances cytolytic activity of Class I-restricted HER-2-specific T lymphocytes against HER-2-overexpressing tumor cells. Cancer Res. 2002, 62:2244-2247.